Congratulate our client and long-term partner, RTI Surgical, on acquiring Paradigm Spine!
RTI Surgical, a global surgical implant company, has signed an agreement to acquire Paradigm Spine, a leader in motion preservation and non-fusion spinal implant technology, in a cash and stock deal valued up to $300m.
Paradigm Spine will receive $100m in cash and 10.7 million shares of RTI Surgical’s common stock worth approximately $50m. The company will also receive milestone payments in cash and RTI common stock.
The acquisition will reduce RTI’s complexity and improve its operational efficiency and growth. It will provide the company with access to Paradigm’s Interlaminar Stabilization device Coflex®, which is available in more than 40 countries. The device is intended to improve the company’s spinal management solution offerings and strengthen its customer base. For press release from RTI, please click HERE.
As a turnkey solution provider for Chinese medtech market, over the years, we helped RTI with China type testing, clinical trial, CFDA (now NMPA) initial registration and renewal for over 20 products, including quantum spinal system, cervical plate, vertebral spacer, fusion instruments, spine fixation system, etc.
For slides on Practical CFDA Clinical Trial Tips that we presented on RAPS in early November, please email info@ChinaMedDevice.com.
China Med Device, LLC (www.ChinaMedDevice.com), a Boston headquartered company, provides regulatory and commercialization turnkey solutions for western medical device, IVD and combination-product companies to enter China. Our NMPA (CFDA) regulatory services include: regulatory strategy, RA, clinical evaluation, clinical trial, QA, GMP and post-market compliance. Our commercialization services include: market assessment research, reimbursement, partnership, distribution qualification and management. We are a NMPA (CFDA) certified legal agent. With offices in Boston and Beijing, we can service our clients 24/7.